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Objectives: This study assessed the impact of discordant empirical antibiotic therapy on the outcome of
bacteremia caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.
Methods: The clinical features and outcomes of a cohort of patients hospitalized with ESBL E. coli
bacteremia between 2007 and 2008 were retrospectively reviewed. The effect of different antimicrobial
regimens on patient outcomes was analyzed.
Results: ESBL E. coli accounted for 24.2% (207/857) of E. coli bacteremia cases. The urinary tract (43.6%)
was the most common source of infection, followed by the hepatobiliary tract (23.0%). Discordant
empirical antibiotic therapy was given to 52.0% patients. Admission to the intensive care unit was
associated with the use of a carbapenem as empirical antibiotic therapy (p < 0.001). Univariate analysis
revealed no signiﬁcant differences in 30-day mortality rates between patients receiving concordant and
discordant empirical antibiotic therapy (23.5% vs. 19.8%, p = 0.526), carbapenem and non-carbapenem
empirical antibiotic therapy (29.8% vs. 19.1%, p = 0.118), beta-lactam/beta-lactam inhibitor combina-
tions (BLBLIs) and non-BLBLIs empirical antibiotic therapy (20.3% vs. 22.3%, p = 0.734), cephalosporin
and non-cephalosporin empirical antibiotic therapy (19.7% vs. 22.6%, p = 0.639), and ﬂuoroquinolone
and non-ﬂuoroquinolone empirical antibiotic therapy (8.3% vs. 22.4%, p = 0.251). The ﬁndings were
conﬁrmed by multivariate analysis.
Conclusions: Despite a high proportion of discordant empirical antibiotic therapy, ESBL production had
little effect on 30-day mortality. Whether the observation can be applied to different ESBL types is
unknown and warrants further study.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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In the last 5 to 10 years, the incidence of infections caused by
Enterobacteriaceae producing extended-spectrum beta-lactamase
(ESBL) has increased rapidly, mainly attributed to the successful
distribution of CTX-M enzymes among Escherichia coli causing
urinary tract and bacteremic infections.1–3 A particularly challeng-
ing issue is that CTX-M-producers are increasingly recovered from
patients with community-onset infections, especially those with
minimal or absent healthcare risks.4We have previously shown that
the CTX-M enzymes are emerging in Hong Kong, China.5–7 Among
female outpatients with urinary tract infections, the prevalence of
ESBL was 6.6% in 2004 and 10% in 2005.6 All ESBL-producers were* Corresponding author.
E-mail address: plho@hkucc.hku.hk (P.-L. Ho).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.09.008found to carry CTX-M-type beta-lactamases.6 For bacteremia, the
ESBL rate for both community-onset and hospital-onset episodes
increased from 8.9% and 20.3%, respectively, in 2000 to 25.5% and
43.5%, respectively, in 2010.8 Consequently, there is a need to assess
how antimicrobial strategies should be modiﬁed to minimize the
impact of antimicrobial resistance on patient care.
As the majority of ESBL-producing E. coli remain susceptible to
the carbapenems, this class of antibiotics is widely accepted as
providing the agents of choice in treating patients with serious or
bacteremic infections caused by such organisms. However,
whether or not other in vitro active agents such as amoxicillin–
clavulanate, piperacillin–tazobactam, and ﬂuoroquinolones can be
administered for the treatment of bacteremia remains controver-
sial.9,10 Furthermore, there is debate on whether the third-
generation cephalosporins are effective against low-minimum
inhibitory concentration (MIC) ESBL-producers.11 While some
studies have demonstrated that inappropriate initial therapy isses. Published by Elsevier Ltd. All rights reserved.
Table 1
Baseline characteristics of the 204 patients with bacteremia due to ESBL-producing
Escherichia coli
Characteristics n (%)
Demographics
Female sex 100 (49.0)
Age 65 years 139 (68.1)
Mean Charlson comorbidity index (IQR) 2 (1–4)
Specialty where ﬁrst positive culture was taken
Medicine 112 (54.9)
Surgery 60 (29.4)
Intensive care unit 8 (3.9)
Accident and emergency 11 (5.4)
Other 13 (6.4)
Source of infection
Urinary tract 89 (43.6)c
Biliary tract/liver 47 (23.0)
Intra-abdominala 14 (6.9)
Pneumonia 11 (5.4)
Otherb 11 (5.4)
Unknown 32 (15.7)
ESBL, extended-spectrum beta-lactamase; IQR, interquartile range.
a Includes peritonitis, pancreatitis, perianal abscess, and diverticulitis.
b Includes neutropenic fever (n = 8), wound infection (n = 2), and catheter-related
infection (n = 1).
c Sixty-four patients did not have a urinary catheter, 21 patients had a urethral
catheter, and four patients had a nephrostomy tube.
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coli,12,13 others have not found such an association, especially in
low-risk bacteremia and when therapy involves agents with some
in vitro activity against the infecting ESBL-producers.14 Therefore,
the present study was conducted to describe the impact of ESBL
production and inappropriate empirical therapy on bacteremia
caused by ESBL-producing E. coli.
2. Methods
2.1. Setting and patient description
This study was performed at Queen Mary Hospital, a 1650-bed
university-afﬁliated teaching hospital. In our hospital, as a general
recommendation for empirical treatment, cefuroxime or amoxi-
cillin–clavulanate are given to patients with mild bacterial
infections, while piperacillin–tazobactam or carbapenems are
reserved for patients with moderate or severe infections.15 Adult
patients aged 18 years and above with bacteremia due to E. coli
from January 2007 to December 2008 were identiﬁed using the
laboratory information system. Each patient was recruited only
once. For patients with more than one episodes of bacteremia, the
ﬁrst episode was used in the analysis. The clinical information of
patients infected with ESBL-producing strains was retrieved from
the Clinical Management System. Patients were excluded if clinical
records were not accessible for review or antibiotics were not given
before death. This study was approved by the Institutional Review
Board of the University of Hong Kong/Hospital Authority Hong
Kong West Cluster.
2.2. Bacterial identiﬁcation and antimicrobial susceptibility testing
The BACTEC 9240 blood culture system (Becton Dickinson, MD,
USA) was used for processing of blood specimens. Bacterial isolates
were identiﬁed using the VITEK GNI system (bioMe´rieux Vitek Inc.,
Hazelwood, MO, USA). Antibiotic susceptibility testing was
performed using the Kirby–Bauer disk diffusion method and
interpreted in accordance with the Clinical and Laboratory
Standards Institute criteria.16
2.3. Deﬁnitions
Healthcare risk factors included hospital onset (ﬁrst positive
blood culture collected 48 h after admission), prior hospitaliza-
tion within 1 year before the positive blood culture, and residency
in a residential care home for the elderly. Community-associated
infection was deﬁned as infection in a patient who did not have any
healthcare risk factors, while hospital-associated infection was
infection in those who had any healthcare risk factor. The Charlson
comorbidity index was used to measure comorbidity using the
International Classiﬁcation of Diseases ninth revision (ICD-9)
coding and veriﬁed by a review of the records.17 Empirical
antibiotic therapy was deﬁned as antibiotics given before the
culture results were reported, whereas known pathogen therapy
was deﬁned as antibiotics given after the culture results were
reported. Concordant therapy was deﬁned as the use of carbape-
nems, beta-lactam/beta-lactam inhibitor combinations (BLBLIs), or
ﬂuoroquinolones to which the isolated strain was susceptible.
Discordant therapy was deﬁned by in vitro resistance to the
antibiotics given. The use of third-generation cephalosporins was
considered to be discordant irrespective of in vitro results.11
2.4. Statistical analysis
The statistical analysis was performed using SPSS software,
version 17.0 for Windows. The Chi-square test was used forcomparison of categorical variables. Univariate and multivariate
analyses were used to assess factors that affect patient outcome.
The following parameters were included in the multivariate
analysis: age, sex, comorbidities, source of infection, and empirical
antibiotic therapy. For the calculation of length of stay, patients for
whom the length of stay could not be determined were excluded. A
p-value of < 0.05 was considered to be statistically signiﬁcant.
3. Results
During the 24-month study period, a total of 857 adult patients
had a positive blood culture for E. coli. Of these, 207 (24.2%) had
ESBL E. coli bacteremia. Two patients were excluded because the
clinical records were not available for review and one patient was
excluded because antimicrobials were not given before death.
Therefore, 204 patients were included in this study (Table 1).
Overall, 8.3% (17/204) were classiﬁed as having community-
associated infections and 91.7% (187/204) as having hospital-
associated infections. Among those with hospital-associated
infections, 32.1% (60/187) were classiﬁed as having a hospital-
onset infection, 38.5% (72/187) were residents of a residential care
home for the elderly, and 89.8% (168/187) had a history of prior
hospitalization within 1 year. More than two-thirds of the patients
were aged 65 years or above. At the time of blood culture
collection, more than 50% of patients were located in the medical
ward. The urinary tract (43.6%) was the most common source of
infection, followed by the hepatobiliary tract (23.0%).
Table 2 shows the results of susceptibility testing. All strains
were susceptible to imipenem. Over 90% of the strains were
susceptible to piperacillin–tazobactam or amikacin.
The use of antibiotics is illustrated in Figure 1. There was no
signiﬁcant difference in the Charlson comorbidity score between
patients with different empirical antibiotic therapy regimens.
Patients who required admission to the intensive care unit were
more likely to receive a carbapenem than those who did not (70%
(14/20) vs. 17.9% (33/184), p < 0.001). Concordant empirical
antibiotic therapy was given to 98 (48.0%) patients, including 22
patients who were concurrently treated with more than one in
vitro active antibiotic. Discordant empirical antibiotic therapy was
given to 106 (52.0%) patients. The mean duration of discordant
Table 2
Antibiotic susceptibility among the 204 ESBL-producing Escherichia coli blood
isolates
Antimicrobial agent Susceptible,
n (%)
Intermediate,
n (%)
Resistant,
n (%)
Amoxicillin–clavulanate 89 (43.6) 91 (44.6) 24 (11.8)
Piperacillin–tazobactam 185 (90.7) 10 (4.9) 9 (4.4)
Ceftriaxonea 10 (4.9) 49 (24.0) 145 (71.1)
Ceftazidimea 174 (85.3) 16 (7.8) 14 (6.9)
Imipenem 204 (100) 0 (0) 0 (0)
Levoﬂoxacinb 74 (36.6) 1 (0.5) 127 (62.9)
Gentamicin 105 (51.5) 1 (0.5) 98 (48.0)
Amikacin 197 (96.6) 5 (2.5) 2 (1.0)
ESBL, extended-spectrum beta-lactamase.
a When results were interpreted as found.
b Levoﬂoxacin results were available for 202 isolates.
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patients (9.3%, including 10 patients on concordant and nine
patients on discordant therapy) died before antibiotic susceptibil-
ity results were reported. Out of the 185 patients with known
pathogen therapy, 154 (83.2%) received concordant known
pathogen therapy. Among patients who did not receive a
carbapenem as empirical antibiotic therapy, 91 (63.6%) received
a carbapenem as known pathogen therapy. For the 52 patients who
did not receive a carbapenem as known pathogen therapy, 20
received BLBLIs (11 amoxicillin–clavulanate, eight piperacillin–
tazobactam, and one ticarcillin–clavulanate), 20 received204a
Group  1
With carbapenem
n=47
14 /47 died
Group  2ab
Other beta -lactam
n=145 
Died before result s reported
n=14
KPT = carbapenem
n=85
9/85 died 
Figure 1. Antimicrobial therapy and outcome in the 204 patients with ESBL-producing
aTwenty-three patients had polymicrobial bacteremia, in which Klebsiella pneumoniae w
species (four patients), Proteus mirabilis (three patients), Pseudomonas aeruginosa (two p
group (one patient), Clostridium species (one patient), Fusobacterium species (one patien
(one patient).
bbeta-Lactam/beta-lactam inhibitor combinations (BLBLIs), n = 74 patients; ﬁrst- or s
(cefotaxime, ceftriaxone, cefoperazone–sulbactam), n = 8 patients. For patients with BL
cFour were concordant and eight were discordant.cefuroxime, seven received ﬂuoroquinolones, and ﬁve received
other antibiotics (two nitrofurantoin, two amikacin, and one co-
trimoxazole).
Overall, the median length of stay was 17 days (interquartile
range 9–33 days). The length of stay could not be determined for a
patient who had been transferred to another hospital and for
another patient who has not been discharged from the hospital at
the time of writing. Twenty (9.8%) patients required admission to
the intensive care unit, of whom 14 (70%) received carbapenem
empirical antibiotic therapy. Forty-four (21.6%) patients died
within 30 days of blood culture collection. Patients without
healthcare risk factors had a signiﬁcantly lower 30-day mortality
rate than those with healthcare risk factors (0% (0/17) vs. 23.5%
(44/187), p = 0.024). There was no statistically signiﬁcant differ-
ence in the 30-day mortality rate between different empirical
antibiotic therapy regimens: concordant vs. discordant (23.5% (23/
98) vs. 19.8% (21/106), p = 0.526), carbapenem (group 1) vs. non-
carbapenem (group 2) (29.8% (14/47) vs. 19.1% (30/157), p = 0.118)
(Figure 1), BLBLIs vs. non-BLBLIs (20.3% (15/74) vs. 22.3% (29/130),
p = 0.734), cephalosporin vs. non-cephalosporin (19.7% (14/71) vs.
22.6% (30/133), p = 0.639), and ﬂuoroquinolone (group 2b) vs. non-
ﬂuoroquinolone (8.3% (1/12) vs. 22.4% (43/192), p = 0.251). When
susceptibility results for the BLBLIs were interpreted as found, the
30-day mortality rates for patients who received concordant and
discordant BLBLIs were 19.1% (9/47) and 22.2% (6/27), respectively
(p = 0.752). When all BLBLIs were considered to be discordant
irrespective of the in vitro result, the mortality rates for concordantGroup  2 
No car bapenem
n=157
KPT = others
n=46
6/46 died
Group  2bc
Fluoroqu inolo ne
n=12
KPT
Carbapenem  n=6 
Other n=6
1/12 died
 Escherichia coli bacteremia (KPT, known pathogen therapy).
as the most common co-isolate (43.5%, 10/23). Other organisms included Bacillus
atients), Enterococcus faecalis (two patients), Bacteroides/non-pigmented Prevotella
t), Peptostreptococcus species (one patient), and coagulase-negative Staphylococcus
econd-generation cephalosporin, n = 63 patients; third-generation cephalosporin
BLIs, 47 (63.5%) were concordant and 27 (36.5%) were discordant.
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and 19.6% (30/153), respectively (p = 0.238). There were no
statistically signiﬁcant differences in the length of stay between
the different empirical antibiotic therapy regimens. In the
multivariate analysis, discordant empirical antibiotic therapy
was not associated with a higher 30-day mortality or longer
length of stay. Among patients who did not receive a carbapenem
as empirical antibiotic therapy (group 2), the 30-day mortality
rates were not signiﬁcantly different between patients who
received a carbapenem as known pathogen therapy and those
who did not (11.0% (10/91) vs. 11.5% (6/52), p = 1.000); between
patients receiving BLBLIs and non-BLBLIs (14.3% (3/21) vs. 10.7%
(13/122), p = 0.626); and between patients who received cepha-
losporins and those who received other antibiotics (15.8% (3/19)
vs. 10.5% (13/124), p = 0.494). Taken together, there was no clear
association between the choice of antimicrobial and outcome.
4. Discussion
Our study showed that a high proportion of patients with ESBL
E. coli bacteremia received initial therapy that was considered to be
inappropriate, because in many of them this involved agents with
little in vitro activity or uncertain efﬁcacy against the infecting
organisms. In most patients, such ‘inappropriate’ (i.e. discordant)
therapy lasted 2–3 days. Our ﬁndings showed that this had little
effect on patient mortality and the length of stay in hospital. In
addition to the relatively short duration of inappropriate therapy,
there were other possible explanations for our ﬁndings. Firstly, the
‘inappropriate’ antibiotics might have had some activity in vivo.
Cephalosporins have been associated with treatment failure, but
they might be effective for infections caused by organisms with
low-MIC ESBL-producers.18 BLBLIs, particularly piperacillin–tazo-
bactam, have been shown to be non-inferior to carbapenems in a
recent post-hoc analysis of six prospective cohorts of ESBL E. coli
bacteremia.9 Secondly, the site of infection is an important
determinant of a patient’s outcome. Almost half of the patients
in our cohort had urinary tract infections. Bacteremia due to
urinary tract infection has been considered to be of low risk.19 The
second most common source was the hepatobiliary tract. Many of
our patients had cholangitis that required biliary drainage. In these
situations, early drainage is more important than antibiotics in
determining a patient’s outcome.20,21 Thirdly, the severity of
disease can affect the outcome. In general, patients with severe
disease are more likely to receive antibiotics with a wider
spectrum or combinations of antibiotics – therapy that is more
likely to be in vitro active. In our cohort, 70% of patients in the
intensive care unit received carbapenems as empirical antibiotic
therapy. Finally, the type of ESBL enzyme may affect the outcome.
In the present study, CTX-M-9 group enzymes predominated
among the ESBL E. coli isolates, and these are often susceptible to
BLBLIs and ceftazidime in vitro.3 By comparison, ESBL E. coli
producers in the UK were often found to have both CTX-M-15 and
OXA-type enzymes and were resistant to BLBLIs and ceftazidime.22
The prevalence of ESBL E. coli strains among cases of E. coli
bacteremia (24.2%) in our study was higher than those reported in
other studies conducted during the same period.22,23 In our
previous study, the incidence density of ESBL E. coli bacteremia
increased from 8.6 per 100 000 patient-days in the years 2000–
2005 to 16.9 per 100 000 patient-days in the years 2006–2010.8
Previously identiﬁed risk factors for ESBL-producers include
healthcare associations such as residency in a residential care
home for the elderly and hospital-onset bacteremia, recent use of
antibiotics, comorbidities, presence of gastrostomy tubes or
urinary catheters, and urinary tract infections.24–26 The baseline
characteristics of our study cohort concur with these known risk
factors. We also found that the ESBL E. coli bacteremia wascommunity-associated in 8.3% of patients. The prevalence of
community-acquired infections has been increasing, and one study
in India showed that up to 46% of Enterobacteriaceae strains from
outpatients were ESBL-producers.27 The increase in community-
acquired ESBL E. coli infection parallels the increasing carriage of
ESBL E. coli in the community. In Hong Kong, stool carriage of ESBL-
producing organisms was found in 43.5% of children who were
admitted for respiratory tract infections and their household
members.28 The rate of ESBL-producers in urine collected from
women in the community now exceeds 5%.6,29 It has been
postulated that an increase in ESBL E. coli in the community is
due to the high rate of antibiotic resistance in food animals.30 In
our locality, there is a high fecal carriage rate of ESBL E. coli in food
animals, exceeding 60% in live pigs and chickens.5 Since ESBL E. coli
bacteremia results in a high mortality, as shown in the current
study (21.6%), controlling the incidence and spread of ESBL E. coli in
the community is very important.
Over 90% of our isolates were susceptible to piperacillin–
tazobactam. The piperacillin–tazobactam susceptible rate in our
cohort was higher than that reported in other studies.31,32 To a
certain extent, such variations in susceptibility reﬂect differences
in the major clonal types and ESBL enzymes. In Hong Kong, the
CTX-M-9 group and CTX-M-14 allele were the predominant ESBL
type.3 Among the patients in the present study, the sequence type
(ST) was determined for the isolates from 116 randomly selected
patients, among whom 30 (25.9%) had an infection with E. coli
belonging to ST131. The remaining isolates included ﬁve ST69,
three ST12, three ST68, and 75 singletons.3 In our study, we also
found a low susceptibility rate to levoﬂoxacin. This is of particular
concern, as patients with contraindications to receiving beta-
lactams, such as allergic reactions, are often given a ﬂuoroquino-
lone as empirical antibiotic therapy. Our results stress the
importance of adding amikacin as empirical antibiotic therapy if
patients are suffering from severe infections.
There are several limitations to this study. Firstly, a retrospec-
tive analysis of factors affecting patient outcome is often affected
by confounding factors. Previous studies have used case–control
methods to adjust for confounding factors, but adjustment for
disease severity is difﬁcult. Secondly, as the attending clinicians
adjusted the antimicrobial regimen according to their clinical
judgment, a patient could have received several classes of
antibiotics as empirical therapy. Therefore, a prospective random-
ized controlled study would be needed to assess the effect of
different therapies. Thirdly, we were not able to analyze the effect
of third-generation cephalosporins as only 4% of the patients
received them as empirical antibiotic therapy.
The results of this study highlight the therapeutic challenges faced
by clinicians in areas where ESBL is highly prevalent. We submit that a
prudent choice of antimicrobial agents according to patient char-
acteristics and disease severity should continue to be practiced.15
Rapid determination of the identity and antibiotic susceptibility of the
organisms is crucial for early optimization of antibiotics, especially for
patients with severe infections. Currently available methods for the
rapid detection of resistant organisms include direct antibiotic
susceptibility testing,33 molecular techniques detecting resistance
genes,34 and matrix-assisted laser desorption ionization–time of ﬂight
mass spectrometry detecting beta-lactamases.35 Optimization of the
treatment strategy for infections caused by ESBL-producers is urgently
needed, since the over-reliance on carbapenems will promote the
emergence of carbapenem-resistant organisms.36
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